Biancaneve
2021-09-13
Hi can someone help me to like my comment? Thank you
IPO Update: Procept BioRobotics Pursues $127 Million IPO
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":888532809,"tweetId":"888532809","gmtCreate":1631505981601,"gmtModify":1631891234435,"author":{"id":3582282988628365,"idStr":"3582282988628365","authorId":3582282988628365,"authorIdStr":"3582282988628365","name":"Biancaneve","avatar":"https://static.tigerbbs.com/c690c91e593d663e5b2aa7fa7a45cead","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hi can someone help me to like my comment? Thank you</p></body></html>","htmlText":"<html><head></head><body><p>Hi can someone help me to like my comment? Thank you</p></body></html>","text":"Hi can someone help me to like my comment? Thank you","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/888532809","repostId":1191352294,"repostType":4,"repost":{"id":"1191352294","kind":"news","pubTimestamp":1631504454,"share":"https://www.laohu8.com/m/news/1191352294?lang=&edition=full","pubTime":"2021-09-13 11:40","market":"us","language":"en","title":"IPO Update: Procept BioRobotics Pursues $127 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1191352294","media":"seekingalpha","summary":"Summary\n\nProcept BioRobotics has filed to raise $127 million in a U.S. IPO.\nThe firm is commercializ","content":"<p><b>Summary</b></p>\n<ul>\n <li>Procept BioRobotics has filed to raise $127 million in a U.S. IPO.</li>\n <li>The firm is commercializing robotic surgical instruments.</li>\n <li>PRCT has grown from a small revenue base and has significant prospects ahead of it, but the IPO is quite highly priced, so I'll pass on it.</li>\n</ul>\n<p><b>Quick Take</b></p>\n<p>Procept BioRobotics Corp. (PRCT) has filed to raise $127 million from the sale of its common stock in an IPO, according to an amendedregistration statement.</p>\n<p>The company develops and commercializes surgical robotic medical devices and instruments.</p>\n<p>While interested investors may wish to bet on high future growth enabling the company to grow into its valuation, the IPO is a bit pricey for me.</p>\n<p><b>Company and Technology</b></p>\n<p>Redwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.</p>\n<p>Management is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.</p>\n<p>The company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>Procept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.</p>\n<p><b>Customer Acquisition</b></p>\n<p>The firm sells its product to hospitals who in turn charge various third party payors for each service rendered.</p>\n<p>The company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.</p>\n<p>Selling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:</p>\n<p><img src=\"https://static.tigerbbs.com/ada5c5e563d998661a4c0be8bd6c8753\" tg-width=\"616\" tg-height=\"303\" referrerpolicy=\"no-referrer\">The Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:</p>\n<p><img src=\"https://static.tigerbbs.com/11297f4daec31c148a6db00152887b6a\" tg-width=\"611\" tg-height=\"242\" referrerpolicy=\"no-referrer\"></p>\n<p><b>Market & Competition</b></p>\n<p>According to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.</p>\n<p>This represents a forecast CAGR of 8.1% from 2018 to 2025.</p>\n<p>The main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.</p>\n<p>Also, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.</p>\n<p>Major competitive or other industry participants include:</p>\n<ul>\n <li>Boehringer Ingelheim</li>\n <li>Allergan</li>\n <li>GlaxoSmithKline(NYSE:GSK)</li>\n <li>Merck(NYSE:MRK)</li>\n <li>Teleflex(NYSE:TFX)</li>\n <li>Boston Scientific(NYSE:BSX)</li>\n <li>Others</li>\n</ul>\n<p><b>Financial Performance</b></p>\n<p>Procept’s recent financial results can be summarized as follows:</p>\n<ul>\n <li>Sharply growing top-line revenue from a small base</li>\n <li>A swing to gross profit and positive gross margin</li>\n <li>High and increasing operating losses</li>\n <li>High and increasing cash used in operations</li>\n</ul>\n<p>Below are relevant financial results derived from the firm’s registration statement:</p>\n<p><img src=\"https://static.tigerbbs.com/b9c04ed344f16f126d4b010418be55b7\" tg-width=\"610\" tg-height=\"615\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/23a43452fa53a29074b6244227c4b5be\" tg-width=\"615\" tg-height=\"618\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/ce774d5bfb2548c261e4065b45be604c\" tg-width=\"614\" tg-height=\"618\" referrerpolicy=\"no-referrer\">As of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.</p>\n<p>Free cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p><b>IPO Details</b></p>\n<p>PRCT intends to sell 5.5 million shares of common stock at a proposed midpoint price of $23.00 per share for gross proceeds of approximately $126.5 million, not including the sale of customary underwriter options.</p>\n<p>No existing shareholders have indicated an interest to purchase shares at the IPO price.</p>\n<p>Assuming a successful IPO at the midpoint of the proposed price range, the company’s enterprise value at IPO (ex-underwriter options) would approximate $674 million.</p>\n<p>Excluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 13.35%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.</p>\n<p>Per the firm’s most recent regulatory filing, it plans to use the net proceeds as follows:</p>\n<blockquote>\n Approximately $45.0 million to hire additional sales and marketing personnel;\n</blockquote>\n<blockquote>\n approximately $25.0 million to fund product development and research and development activities; and\n</blockquote>\n<blockquote>\n the remainder for working capital and other general corporate purposes.\n</blockquote>\n<blockquote>\n Based on our operating plan, we currently believe that our existing cash and cash equivalents, anticipated revenue and available debt financing arrangements, together with the net proceeds from this offering, will be sufficient to meet our capital requirements and fund our operations through at least the next 12 months from the date of this prospectus.\n</blockquote>\n<p>Management’s presentation of the company roadshow is not available.</p>\n<p>Regarding outstanding legal proceedings, management has disclosed no legal claims or proceedings against the firm of a material nature.</p>\n<p>Listed bookrunners of the IPO are BofA Securities, Goldman Sachs, Cowen, Guggenheim Securities and SVB Leerink.</p>\n<p><b>Valuation Metrics</b></p>\n<p>Below is a table of the firm’s relevant capitalization and valuation metrics at IPO, excluding the effects of underwriter options:</p>\n<p><img src=\"https://static.tigerbbs.com/84ef95ffd4e0d8ccce8c39b6a56daa28\" tg-width=\"611\" tg-height=\"707\" referrerpolicy=\"no-referrer\">As a reference, a potential partial public comparable would be Teleflex; shown below is a comparison of their primary valuation metrics:</p>\n<p><img src=\"https://static.tigerbbs.com/d65054ebfd91972cd98791ee6860e9a8\" tg-width=\"610\" tg-height=\"359\" referrerpolicy=\"no-referrer\">Commentary</p>\n<p>PRCT seeks public investment to fund the commercial ramp up of its AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.</p>\n<p>The firm’s financials show strong revenue growth from a small base but high operating losses and cash use as the company is in the early stages of its commercialization process.</p>\n<p>Free cash flow for the twelve months ended June 30, 2021, was negative ($52.7 million).</p>\n<p>The IPO proceeds will likely only last the firm 12 months, so PRCT will need to go out for more capital soon, either diluting shareholders with a new equity sale or taking on debt.</p>\n<p>Sales and Marketing expenses as a percentage of total revenue have dropped as revenue has begun to ramp up and its Sales and Marketing efficiency rate rose to 0.6x in the most recent six-month reporting period.</p>\n<p>The market opportunity for treating benign prostate hyperplasia is large and expected to double in size between 2017 and 2025.</p>\n<p>BofA Securities is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 13.5% since their IPO. This is a mid-tier performance for all major underwriters during the period.</p>\n<p>The primary risk to the company’s outlook is the slow sales cycle and uptake of the firm’s system, which may be perceived as more complex than handing out a prescription pill for patient use.</p>\n<p>As for valuation, management is seeking a Price/Sales multiple of 45x, which is extremely high and appears to be based on expected future growth.</p>\n<p>While interested investors may wish to bet on that high future growth enabling the company to grow into its valuation, the IPO is a bit pricey for me.</p>\n<p>Expected IPO Pricing Date: September 14, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Update: Procept BioRobotics Pursues $127 Million IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Update: Procept BioRobotics Pursues $127 Million IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-13 11:40 GMT+8 <a href=https://seekingalpha.com/article/4454431-ipo-update-procept-biorobotics-pursues-127-million-ipo><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nProcept BioRobotics has filed to raise $127 million in a U.S. IPO.\nThe firm is commercializing robotic surgical instruments.\nPRCT has grown from a small revenue base and has significant ...</p>\n\n<a href=\"https://seekingalpha.com/article/4454431-ipo-update-procept-biorobotics-pursues-127-million-ipo\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PRCT":"PROCEPT BioRobotics"},"source_url":"https://seekingalpha.com/article/4454431-ipo-update-procept-biorobotics-pursues-127-million-ipo","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1191352294","content_text":"Summary\n\nProcept BioRobotics has filed to raise $127 million in a U.S. IPO.\nThe firm is commercializing robotic surgical instruments.\nPRCT has grown from a small revenue base and has significant prospects ahead of it, but the IPO is quite highly priced, so I'll pass on it.\n\nQuick Take\nProcept BioRobotics Corp. (PRCT) has filed to raise $127 million from the sale of its common stock in an IPO, according to an amendedregistration statement.\nThe company develops and commercializes surgical robotic medical devices and instruments.\nWhile interested investors may wish to bet on high future growth enabling the company to grow into its valuation, the IPO is a bit pricey for me.\nCompany and Technology\nRedwood City, California-based Procept was founded to develop advanced surgical robotic devices for use in minimally invasive procedures.\nManagement is headed by President and CEO Reza Zadno, Ph.D., who has been with the firm since February 2020 and was previously president and CEO of Avedro, a healthcare company.\nThe company's first instrument is the AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nProcept has received at least $328 million in equity investment from investors including CPMG, Viking Global, Fidelity and individuals.\nCustomer Acquisition\nThe firm sells its product to hospitals who in turn charge various third party payors for each service rendered.\nThe company is targeting 860 high-volume hospitals which account for 70% of all hospital-based resective procedures.\nSelling, G&A expenses as a percentage of total revenue have dropped substantially as revenues have increased, as the figures below indicate:\nThe Selling, G&A efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling, G&A spend, rose to 0.6x in the most recent reporting period, as shown in the table below:\n\nMarket & Competition\nAccording to a 2018 marketresearch reportby Allied Market Research, the global market for treating benign prostatic hyperplasia was an estimated $10.7 billion in 2017 and is forecast to reach $20.1 billion by 2025.\nThis represents a forecast CAGR of 8.1% from 2018 to 2025.\nThe main drivers for this expected growth are an increase in disease incidence to the aging of the global population of males.\nAlso, alpha-blocker drugs are likely to be a major competitor, as they help in relaxing the muscle of the prostate and the bladder neck, allowing urination to occur more easily.\nMajor competitive or other industry participants include:\n\nBoehringer Ingelheim\nAllergan\nGlaxoSmithKline(NYSE:GSK)\nMerck(NYSE:MRK)\nTeleflex(NYSE:TFX)\nBoston Scientific(NYSE:BSX)\nOthers\n\nFinancial Performance\nProcept’s recent financial results can be summarized as follows:\n\nSharply growing top-line revenue from a small base\nA swing to gross profit and positive gross margin\nHigh and increasing operating losses\nHigh and increasing cash used in operations\n\nBelow are relevant financial results derived from the firm’s registration statement:\nAs of June 30, 2021, Procept had $159.2 million in cash and $68.3 million in total liabilities.\nFree cash flow during the twelve months ended June 30, 2021, was negative ($52.7 million).\nIPO Details\nPRCT intends to sell 5.5 million shares of common stock at a proposed midpoint price of $23.00 per share for gross proceeds of approximately $126.5 million, not including the sale of customary underwriter options.\nNo existing shareholders have indicated an interest to purchase shares at the IPO price.\nAssuming a successful IPO at the midpoint of the proposed price range, the company’s enterprise value at IPO (ex-underwriter options) would approximate $674 million.\nExcluding effects of underwriter options and private placement shares or restricted stock, if any, the float to outstanding shares ratio will be approximately 13.35%. A figure under 10% is generally considered a ‘low float’ stock which can be subject to significant price volatility.\nPer the firm’s most recent regulatory filing, it plans to use the net proceeds as follows:\n\n Approximately $45.0 million to hire additional sales and marketing personnel;\n\n\n approximately $25.0 million to fund product development and research and development activities; and\n\n\n the remainder for working capital and other general corporate purposes.\n\n\n Based on our operating plan, we currently believe that our existing cash and cash equivalents, anticipated revenue and available debt financing arrangements, together with the net proceeds from this offering, will be sufficient to meet our capital requirements and fund our operations through at least the next 12 months from the date of this prospectus.\n\nManagement’s presentation of the company roadshow is not available.\nRegarding outstanding legal proceedings, management has disclosed no legal claims or proceedings against the firm of a material nature.\nListed bookrunners of the IPO are BofA Securities, Goldman Sachs, Cowen, Guggenheim Securities and SVB Leerink.\nValuation Metrics\nBelow is a table of the firm’s relevant capitalization and valuation metrics at IPO, excluding the effects of underwriter options:\nAs a reference, a potential partial public comparable would be Teleflex; shown below is a comparison of their primary valuation metrics:\nCommentary\nPRCT seeks public investment to fund the commercial ramp up of its AquaBeam Robotic System for use in urologic surgery with an initial focus on treating benign prostate hyperplasia.\nThe firm’s financials show strong revenue growth from a small base but high operating losses and cash use as the company is in the early stages of its commercialization process.\nFree cash flow for the twelve months ended June 30, 2021, was negative ($52.7 million).\nThe IPO proceeds will likely only last the firm 12 months, so PRCT will need to go out for more capital soon, either diluting shareholders with a new equity sale or taking on debt.\nSales and Marketing expenses as a percentage of total revenue have dropped as revenue has begun to ramp up and its Sales and Marketing efficiency rate rose to 0.6x in the most recent six-month reporting period.\nThe market opportunity for treating benign prostate hyperplasia is large and expected to double in size between 2017 and 2025.\nBofA Securities is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 13.5% since their IPO. This is a mid-tier performance for all major underwriters during the period.\nThe primary risk to the company’s outlook is the slow sales cycle and uptake of the firm’s system, which may be perceived as more complex than handing out a prescription pill for patient use.\nAs for valuation, management is seeking a Price/Sales multiple of 45x, which is extremely high and appears to be based on expected future growth.\nWhile interested investors may wish to bet on that high future growth enabling the company to grow into its valuation, the IPO is a bit pricey for me.\nExpected IPO Pricing Date: September 14, 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":247,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":42,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/888532809"}
精彩评论